It is overexpressed in the majority of cancers and acts as a modulator of several cancer-driving signalling pathways, including c-MYC, NOTCH1, WNT/β-catenin and RAS/MEK/ERK pathways, while it simultaneously curbs several tumour suppressors5. This evidence concerns the gene MAP2K7 and cancer.